Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Butenafine - Kaken Pharmaceutical

Next Previous
X
Search
Drug Profile

Butenafine - Kaken Pharmaceutical

Alternative Names: Butena; Butenafide; Butenafide hydrochloride; Butenafine hydrochloride; Dermacom; Dermax; Dr. Scholl's; Fintop; Funcid; Ingebut; KP 363; Lotrimin Ultra; Mentax; Volley; Zaxem

Latest Information Update: 25 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kaken Pharmaceutical
  • Developer Kaken Pharmaceutical; Merck & Co
  • Class Antifungals; Naphthalenes; Small molecules
  • Mechanism of Action Squalene monooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mycoses; Onychomycosis; Pityriasis versicolor; Tinea corporis; Tinea cruris; Tinea pedis

Most Recent Events

  • 10 Jul 2007 No development reported - Phase-III for Onychomycosis in USA (PO)
  • 07 Sep 2004 Added Sinphar and Hanlim to Company table
  • 10 Jul 2004 Launched for Mycoses in China (Topical)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top